Alnylam Pharmaceuticals this week provided an update on its flagship TTR-mediated amyloidosis drug ALN-TTR02, stating that it has begun enrollment in an open-label extension study of a recently completed phase II trial and unveiling the compound's international nonproprietary name — patisiran.

A phase III trial of the agent remains on track to begin before the end of this year, alongside a subcutaneous version that is poised to advance into phase II, the company said during an announcement of its third quarter financial results.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

In Cell this week: biobank of colorectal cancer organoids, ancient wolf genome analysis, and more.

With cloud computing becoming more attractive to researchers, Nature News offers some tips on how to get going.

In a series of articles, medical journals debate the necessity of conflict-of-interest policies.

Irwin Rose, who won the 2004 Nobel Prize in Chemistry for his work on ubiquitin-mediated protein degradation, has died.